Table 1.

Patient characteristics, cancer characteristics, immune-related dermatological side effect and treatments.

Patient	Sex	Age (years)	Cancer	Cancer treatment	irAEs	irAE treatment	Dupilumab dosage	Cancer outcome
1	M	74	Recurrent invasive cutaneous SCC and metastatic melanoma	Cemiplimab (PD1 inhibitor)	Eczema and pruritus	- Topical steroids - Oral antihistamine	Loading dose 600 mg followed by 300 mg every other week	SCC complete response and metastatic melanoma partial response
2	M	78	Stage IIIC cutaneous melanoma	Adjuvant nivolumab (PD1 inhibitor)	BP	- Topical steroids - Oral prednisone	Loading dose 600 mg followed by 300 mg every other week	Remission
3	F	70	Metastatic serous endometrial carcinoma	Pembrolizumab (PD1 inhibitor) and Lenvatinib (multi-target tyrosine kinase inhibitor)	BP	- Topical steroids - Doxycycline - Nicotinamide - Oral prednisone - Mycophenolate mofetil	Loading dose 600 mg followed by 300 mg every other week	Death from cancer progression

BP: Bullous pemphigoid; SCC: squamous cell carcinoma.PD1: programmed cell death 1; irAE: immune-related adverse event.

Informed consent to receive dupilumab as an off-label medication for irAEs was obtained from all our patients after a thorough discussion involving their medical oncologist.